You are here

Article Text

Article menu
Download PDFPDF
Editor's quiz: GI snapshot
To resect or not to resect? That is the question
  1. Mazen Noureddin1,
  2. David E Kleiner2,
  3. Ahmed M Gharib3,
  4. Gennady Bratslavsky4,
  5. Theo Heller1
  1. 1Liver Diseases Branch, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Maryland, USA
  2. 2Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Maryland, USA
  3. 3Integrative Cardiovascular Imaging Section, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Maryland, USA
  4. 4Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Maryland, USA
  1. Correspondence to Dr Mazen Noureddin, Liver Diseases Branch, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bldg 10 Room 4-5722, Clinical Center, Bethesda, Maryland 20892, USA; noureddinm{at}niddk.nih.gov

https://doi.org/10.1136/gut.2010.221440

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinical presentation

    A 54-year-old Caucasian female, with a strong family history of renal cell carcinoma, presented with a left kidney lesion. She had a hysterectomy 20 years ago and no significant history of oral contraceptive use. During the current evaluation, she was found to have two hypervascular lesions in the left lobe of the liver in addition to a fatty liver on CT scan as well as MRI (figure 1A–C). The largest lesion was 2 cm in size. She was asymptomatic. Physical examination showed an obese woman with body mass index of 35.6 with an otherwise normal exam. Her laboratory results showed an aspartate aminotransferase of 88 U/l, alanine aminotransferase of 75 U/l, alkaline phosphatase of 93 U/l, total bilirubin of 0.6 mg/dl and …

    View Full Text

    Footnotes

    • Funding The Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and NIDDK.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval This study was conducted with the approval of the NIH IRB.

    • Provenance and peer review Not commissioned; externally peer reviewed.